Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-05 Metformin in Combination With Crizotinib for the Treatment of EML4-ALK+ Lung Cancer

Journal of Thoracic Oncology

English

P1.12-13 Impact of Chronic Obstructive Pulmonary Disease on the Survival of Patients With Extensive-Disease Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P2.09-23 a Combination of Podoplanin and E-Cadherin Expression in Lung SqCC May Be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.

Journal of Thoracic Oncology

English

P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance

Journal of Thoracic Oncology

English

MA06.06 an Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti-Tumor Efficacy

Journal of Thoracic Oncology

English

Radiologic Response to Neoadjuvant Treatment Predicts Histologic Response in Thymic Epithelial Tumors

Journal of Thoracic Oncology

English

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Journal of Thoracic Oncology

English

Circulating Tumor Microemboli Diagnostics for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Pulmonary

P3.15-21 Real-World Experience of First-Line Afatinib Treatment in Patients With EGFR Mutant Advanced Non-Small Cell Lung Cancer

Association of Exon 19 and 21 EGFR Mutation Patterns With Treatment Outcome After First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer

P1.01-05 Metformin in Combination With Crizotinib for the Treatment of EML4-ALK+ Lung Cancer

P1.12-13 Impact of Chronic Obstructive Pulmonary Disease on the Survival of Patients With Extensive-Disease Small Cell Lung Cancer

P2.09-23 a Combination of Podoplanin and E-Cadherin Expression in Lung SqCC May Be a Poor Prognostic Indicator: A Propensity Score-Matched Analysis.

P1.13-15 Detection of EGFR Mutations in cfDNA and Development of Resistance

MA06.06 an Ex-Vivo Patient-Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti-Tumor Efficacy

Radiologic Response to Neoadjuvant Treatment Predicts Histologic Response in Thymic Epithelial Tumors

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Circulating Tumor Microemboli Diagnostics for Patients With Non–Small-Cell Lung Cancer